The goal of the Molecular Transducers of Physical Activity Consortium (MoTrPAC) is to assess
molecular changes that occur in response to physical activity (PA). To achieve this aim, a
mechanistic randomized controlled trial (RCT) is conducted, in which adult study participants
are randomized to endurance exercise (EE) training, resistance exercise (RE) training, or no
exercise Control for a period of approximately 12 weeks. The overarching hypothesis is that
there are discoverable molecular transducers that communicate and coordinate the effects of
exercise on cells, tissues, and organs, which may initiate processes ultimately leading to
the health benefits of exercise. Because this is a mechanistic trial, the main goal is not a
health-related outcome. Rather, the goal is to generate a map of the molecular responses to
exercise that will be used by the Consortium and by the scientific community at large to
generate hypotheses for future investigations of the health benefits of PA.
Study assessments are completed before and after the intervention period (exercise or
control), and at specific interim time points during the course of the intervention.
Assessments include measurements of cardiorespiratory fitness, muscular strength, and body
composition (including total body bone mineral content) determined by dual-energy x-ray
absorptiometry (DXA). There is also collection of blood and muscle and adipose tissue
biospecimens, monitoring of free-living PA level using wearable devices, and completion of
participant reported outcomes and health status by interview and/or questionnaire. An
additional group of highly active (HA) individuals currently active in either EE (HAEE) or RE
(HARE) are recruited for a single acute exercise testing session of either endurance or
resistance exercise and other study assessments. MoTrPAC participants are recruited, trained,
and assessed via six adult Clinical Centers (CC), involving 10 clinical sites. As part of the
MoTrPAC functions, participant data and biological samples are transferred from the clinical
sites to the Consortium Coordinating Center (CCC) Data Management, Analysis and Quality
Control Center (DMAQC)and to the Biological Sample Repository, and later analyzed by the
Consortium Chemical Analysis Sites (CAS) and the Bioinformatics Center (BIC).
Biological samples collected in this project undergo molecular phenotyping, including
metabolomic, lipidomic, proteomic, epigenomic, transcriptomic, and genomic analyses. These
assays are done at the MoTrPAC CAS.
Overall coordination of the study and analyses occurs at 4 institutions which make up the CCC
and the BIC.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.